Generate Biomedicines (GENB) vs Nuvation Bio (NUVB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Generate Biomedicines is the larger company by market cap ($1.80 billion vs $1.74 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GENB | NUVB |
|---|---|---|
| Share price | $13.99 | $4.95 |
| Market cap | $1.80B | $1.74B |
| 1-day change | +3.10% | +1.85% |
| YTD return | — | -45.76% |
| 1-year return | — | +32.79% |
| 5-year return | — | -49.11% |
| EPS (TTM) | $-2.44 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.67 | $9.75 |
| 52-week low | $11.00 | $3.36 |
| Distance from 52-week high | -38.29% | -49.23% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +92.99% | +162.63% |
| Average volume | 1.04M | 5.65M |
| Shares outstanding | 128.35M | 350.12M |
| Employees | 312 | 305 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Generate Biomedicines
GENB stock →Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees
About Nuvation Bio
NUVB stock →Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 305 employees
GENB vs NUVB FAQ
Which is bigger, Generate Biomedicines or Nuvation Bio?
Generate Biomedicines (GENB) is larger, with a market capitalization of $1.80B compared with $1.74B for Nuvation Bio (NUVB).
Are Generate Biomedicines and Nuvation Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.